लोड हो रहा है...
Secukinumab: A Review in Ankylosing Spondylitis
Secukinumab (Cosentyx(®)), a first-in-class fully human monoclonal antibody against interleukin-17A, is approved in several countries, including the USA and those of the EU, for the treatment of ankylosing spondylitis (AS). Subcutaneous secukinumab significantly improved the clinical signs and sympt...
में बचाया:
| में प्रकाशित: | Drugs |
|---|---|
| मुख्य लेखक: | |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Springer International Publishing
2019
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6422944/ https://ncbi.nlm.nih.gov/pubmed/30793255 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-019-01075-3 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|